Outpatient injections for multiple myeloma with teclistamab or talquetamab
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 2 trial tests two antibody medicines (teclistamab or talquetamab) given as outpatient injections, to treat multiple myeloma. It also tests preventing and treating side effects with supportive medicines, aiming to improve disease control in people who have already tried other myeloma treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can sign consent
- You have confirmed multiple myeloma (MM) based on standard criteria
- You have tried prior MM medicines: either a specific mix of at least 2 prior treatments (if assigned to teclistamab/talquetamab plus tocilizumab) or at least 1 prior treatment (if assigned to teclistamab plus oral dexamethasone)
- Your overall health is high enough for the trial: ECOG activity level 0–1 (or 0–2 for the teclistamab + oral dexamethasone group)
- Your myeloma is measurable or you have plasmacytomas that meet size limits
- You can meet close monitoring rules after step-up dosing (staying near the site and having an adult with you)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial tests two different drug combinations to treat newly diagnosed multiple myeloma. It may help by aiming to control the cancer without using high-dose chemotherapy and stem cell transplant for people who can’t receive that approach.
This Phase 2 study tests a study treatment in adults with multiple myeloma that needs treatment. It may help by trying to improve disease control after you’ve had (or are scheduled to have) standard therapy like chemotherapy and stem cell transplant for some people.
This trial tests a new treatment for people with newly diagnosed multiple myeloma that has not been treated before. It looks at whether adding a targeted therapy to standard treatment helps control the disease better.
This study tests whether giving the drug teclistamab (a treatment for multiple myeloma) in an outpatient setting is safe and works well. You may qualify if you have had at least three prior treatments, have a caregiver to support you, and meet other health criteria.
This Phase 2 trial studies how well teclistamab works when used in combination for people age 65 and older with multiple myeloma. It aims to see whether this treatment can control the cancer safely in older patients who may not do high-dose chemotherapy or stem cell transplant.
This trial tests two drugs (talquetamab and teclistamab) to see if they can eliminate remaining cancer cells in newly diagnosed myeloma patients who have already had a stem cell transplant. It may be an option if you have minimal residual disease (MRD) and a good response to initial treatment.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.